Literature DB >> 3339265

Rapid and sensitive analysis of 8-methoxypsoralen in plasma.

F P Gasparro1, J Battista, J Song, R L Edelson.   

Abstract

A new method has been developed to extract 8-methoxypsoralen (8-MOP) from human plasma and to prepare samples for high performance liquid chromatography (HPLC) analysis. Plasma samples are passed through solid phase extraction cartridges that are essentially HPLC "microcolumns" consisting of a bonded silica sorbent that, after activation, selectively retain 8-MOP and then release it when exposed to an eluting solvent. The 8-MOP collected from the cartridge is analyzed by reversed phase HPLC. With this new technique, the 8-MOP is completely recovered and as little as 10 ng/ml can be detected in a 1-ml plasma sample. The average plasma level in a series of 17 patients who had ingested Oxsoralen (approximately 0.6 mg/kg) was 117 ng/ml (+/- 79).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3339265     DOI: 10.1111/1523-1747.ep12462304

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

1.  The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans.

Authors:  V Billard; P L Gambus; J Barr; C F Minto; L Corash; J W Tessman; J L Stickney; S L Shafer
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

2.  Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.

Authors:  P W Heald; M I Perez; I Christensen; N Dobbs; G McKiernan; R Edelson
Journal:  Yale J Biol Med       Date:  1989 Nov-Dec

Review 3.  Molecular aspects of extracorporeal photochemotherapy.

Authors:  F P Gasparro; R Dall'Amico; D Goldminz; E Simmons; D Weingold
Journal:  Yale J Biol Med       Date:  1989 Nov-Dec

4.  Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity.

Authors:  Yusuf Y Deeni; Sally H Ibbotson; Julie A Woods; C Roland Wolf; Gillian Smith
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.